Iguratimod - SimcereAlternative Names: Iremod
Latest Information Update: 07 May 2012
At a glance
- Originator Simcere Pharmaceutical Group
- Class Analgesics; Anti-inflammatories; Antipyretics; Antirheumatics; Benzopyrans; Chromones; Small molecules; Sulfonamides
- Mechanism of Action Cyclo-oxygenase 2 inhibitors; Cytokine inhibitors; Tumour necrosis factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Marketed Rheumatoid arthritis
Most Recent Events
- 08 Jan 2012 Launched for Rheumatoid arthritis in China (PO)
- 25 Aug 2011 Registered for Rheumatoid arthritis in China (PO)
- 25 Aug 2011 Registered for Osteoarthritis in China (PO)